PAS
EGRX

Point72 Asia (Singapore)’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Point72 Asia (Singapore)’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-7,773
Closed -$29K – 1308
2024
Q3 		$29K Sell
7,773
-3,839
-33% -$18.3K 0.01% 770
2024
Q2 		$65K Buy
+11,612
New +$50.6K 0.01% 583
2024
Q1 		– Sell
-2,100
Closed -$11K – 1274
2023
Q4 		$11K Buy
+2,100
New +$20.7K ﹤0.01% 496

Other funds holding EGRX

XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
Simplex Trading
Simplex Trading Chicago, Illinois $149B AUM 62.07% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return
SLG
Stanley-Laman Group Berwyn, Pennsylvania $814M AUM 40.24% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
AIC
Archer Investment Corporation Carmel, Indiana $508M AUM 24.79% 1-Year Est. Return
Credit Agricole
Credit Agricole Montrouge Cedex, France $38.1B AUM
FFA
Farther Finance Advisors San Francisco, California $12.8B AUM 26.53% 1-Year Est. Return

Point72 Asia (Singapore)'s EGRX Position: Q4 2024 in Review

Point72 Asia (Singapore) sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q4 2024, closing a stake of 7,773 shares — an estimated $29K sold.

Point72 Asia (Singapore) first reported a position in EGRX in Q4 2023 and held it in 3 quarters. The position peaked at $65K in Q2 2024. 9 funds tracked by Wall St. Rank hold EGRX as of Q4 2024.

  • Point72 Asia (Singapore) reported no remaining Eagle Pharmaceuticals, Inc. position as of Q4 2024 after selling out during the quarter.
  • Point72 Asia (Singapore) sold 7,773 Eagle Pharmaceuticals, Inc. shares in Q4 2024, an estimated $29K.
  • Point72 Asia (Singapore) first reported a position in Eagle Pharmaceuticals, Inc. in Q4 2023 and held it in 3 quarters.
  • Point72 Asia (Singapore)'s Eagle Pharmaceuticals, Inc. position peaked at $65K in Q2 2024.
  • 9 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q4 2024.

Based on Point72 Asia (Singapore)'s 13F filing for Q4 2024, filed 14 Feb 2025.